Anti Cd 20 Ocrevus denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Ocrevus

Ocrevus (ocrelizumab) is a specialty infused biologic for multiple sclerosis, and Aetna requires prior authorization (PA) for it under virtually all plan designs. A prior-auth-required denial typically means either (a) the drug was dispensed or infused before PA was obtained, (b) the PA request was submitted but denied because it did not satisfy Aetna's clinical criteria, or (c) an existing PA has expired and was not renewed before the next infusion.

If the PA was simply not requested in advance, the first step is submitting one now — with a retroactive appeal if the infusion has already occurred. If the PA was denied on clinical grounds, the appeal arguments in the medical-necessity section apply.

## Federal Appeal Rights

• Internal appeal: Under ERISA §503 or ACA rules, you can appeal any adverse benefit determination, including a PA denial. The deadline is on the denial letter.
• Retroactive PA / claim appeal: If Ocrevus was administered without PA and Aetna denied the claim, you may appeal with documentation showing the treatment was medically necessary. Some plans waive PA requirements if the treating facility or prescriber made a good-faith administrative error.
• External review: Under ACA §2719, if the internal appeal fails, external review by an IRO is available, typically within approximately four months of the final internal denial.
• Expedited PA: If the patient requires an infusion imminently and standard PA turnaround would create a health risk, request expedited prior-authorization review. The neurologist must document the urgency.

## What to Gather

1. Aetna's PA criteria for ocrelizumab — download the current clinical policy bulletin. Identify every criterion Aetna requires for approval and collect documentation for each. 2. Diagnosis and disease-activity records — neurologist notes, MRI reports, relapse history, and functional status documentation. 3. Prior DMT history — if Aetna's PA criteria require documentation of prior therapy, compile a complete medication history with start/stop dates and reasons for discontinuation. 4. Prescriber medical-necessity letter — the neurologist should address each PA criterion explicitly, in the order Aetna lists them. 5. Infusion scheduling documentation — if this is a renewal PA, include the prior approval letter and infusion history to demonstrate the patient is an established, stable Ocrevus patient.

## Criteria-Mapping Structure

| Aetna PA Criterion | Supporting Documentation | |---|---| | Confirmed MS diagnosis with subtype | Neurologist note + MRI | | Specialist prescriber | Neurologist credentials | | Prior therapies documented (if required) | Medication history with dates/reasons | | FDA label-consistent dosing planned | Prescriber order; confirm against current label | | Renewal: ongoing response / no safety concern | Most recent neurologist visit note |

If Aetna denied a PA on clinical grounds, treat the PA denial exactly like a medical-necessity denial and apply the same documentation strategy. Always request a peer-to-peer review between the neurologist and Aetna's medical director before escalating to formal appeal.